Coordination with prescribing clinicians
doi: 10.3389/fendo.2024.1330936 Received 31 October 2023 Accepted 02 January 2024 Published 06 February 2024 Volume 15 - 2024 Edited by Julianne Hall, Quinnipiac University, United States Reviewed by Eric Morris Bomberg, University of Minnesota, United States Michihiro Takahashi, Takahashi Psychiatric Clinic, Japan Updates Copyright 2024 Chen, Cai, Zou and Fu
Yes, semaglutide is often prescribed for individuals with high blood pressure, as weight loss can frequently lead to improvements in blood pressure readings
Researchers repeatedly identify reduced intake as a major reason nutritional side effects may develop during GLP-1 therapy
Currently, only two GLP-1s are approved by the FDA to treat obesity: Wegovy and Saxenda (liraglutide)